

Influence of Phototherapy on Markers of Apoptosis in Full-Term Infants

Thesis

*Submitted for Partial Fulfillment of Master Degree
in Pediatric Medicine*

Presented by

Mahmoud Abou Atteya Hassan Sakr

M.B.B.Ch, 2012

Faculty of Medicine, Menofia University

Under the supervision of

Prof. Dr. Mohsen Saleh El-Alfy

Professor of Pediatrics

Faculty of Medicine- Ain Shams University

Prof. Dr. Safaa Shafik

Professor of Pediatrics

Faculty of Medicine- Ain Shams University

Dr. Fatma Abdelhamid Ibrahim

Assistant Professor in Biochemistry Department

National Research Centre, Dokki

Faculty of Medicine - Ain Shams University

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Mohsen Saleh El-Alfy**, Professor of Pediatrics - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Safaa Shafik**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Fatma Abdelhamid Ibrahim**, Assistant Professor in Biochemistry Department, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Mahmoud Abou Atteya Hassan Sakr

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iv
List of Abbreviations	vii
Abstract	viii
Introduction	1
Aim of the Work.....	3
Review of Literature	
▪ Neonatal Hyperbilirubinemia	4
▪ Phototherapy	35
▪ Apoptosis	52
▪ P53 Gened	66
Patients and Methods	77
Results	90
Discussion	117
Limitations of the Study	124
Conclusion.....	125
Recommendations	126
Summary	127
References	129
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Risk factors for hyperbilirubinemia	13
Table (2):	Risk factors for the development of severe hyperbilirubinemia:	16
Table (3):	Other classification of neonatal hyperbilirubinemia according to the age of onset and type of bilirubin.	17
Table (4):	Factors that exacerbate physiological jaundice leading to high serum bilirubin levels.....	22
Table (5):	Criteria that rule out the diagnosis of physiologic jaundice	22
Table (6):	Classification of Neonatal Hyperbilirubine-mia Based on Mechanism of Accumulation.....	30
Table (7):	Congenital non-hemolytic unconjugated hyperbilirubinemia	31
Table (8):	Comparison between control and patients groups regarding age and sex.....	90
Table (9):	Average initial data collected from patients group.	91
Table (10):	Average bilirubin measured from patients group (before phototherapy, before discontinuation and 72 hrs after discontinuation.	92
Table (11):	Comparison between control and patients groups regarding P53, MDA*, GSH*, SOD* and GPx* (before phototherapy).	93

List of Tables

Table No.	Title	Page No.
Table (12):	Comparison between control and patients groups as regarding P53, MDA*, GSH*, SOD* and GPx* (before discontinuation of phototherapy).	96
Table (13):	Comparison between control and patients groups regarding P53 MDA*, GSH*, SOD* & GPx* (72 hrs after discontinuation of phototherapy).....	99
Table (14):	Demographic data collected from patients.....	102
Table (15):	Comparison among patients group regarding bilirubin, P53, MDA*, GSH*, SOD* & GPx*.....	103
Table (16):	Correlation between studied parameters of patients group (before phototherapy).....	106
Table (17):	Correlation between studied parameters of patients group (before discontinuation of phototherapy).....	108
Table (18):	Correlation between studied parameters of patients group (72 hrs after discontinuation of phototherapy).....	110
Table (19):	Comparison between males and females as regarding bilirubin, P53, MDA*, GSH*, SOD* and GPx* (before, before discontinuation of phototherapy and 72 hrs after discontinuation of phototherapy)	112

List of Tables (cont...)

Table No.	Title	Page No.
Table (20):	Comparison between gravidity of patients group mothers (primigravida or multigravida) as regarding bilirubin, P53, MDA*, GSH*, SOD* and GPx* (before phototherapy, before discontinuation of phototherapy and 72 hrs after discontinuation of phototherapy).....	114
Table (21):	Comparison between mode of delivery (NVD*, CS*) of mothers as regarding bilirubin, P53, MDA*, GSH*, SOD* and GPx* (before phototherapy, before discontinuation of phototherapy and 72 hrs after discontinuation of phototherapy)	115

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Biosynthesis of bilirubin.....	7
Figure (2):	Neonatal bile pigment metabolism	8
Figure (3):	Bilirubin transport and conjugation	12
Figure (4):	39
Figure (5):	Infant under Ohmeda halogen lamp with eye protection.	45
Figure (6):	Infant under neoBLUE phototherapy light and lying on fiberoptic phototherapy blanket.....	47
Figure (7):	neoBLUE light-emitting diode (LED) phototherapy system.	48
Figure (8):	Cellular events in apoptosis.....	53
Figure (9):	Morphology of necrosis and apoptosis	56
Figure (10):	Intrinsic and extrinsic pathways of apoptosis.....	61
Figure (11):	Structure of p53.....	67
Figure (12):	Comparison between controls and patients groups as regarding P53 (before phototherapy).....	94
Figure (13):	Comparison between controls and patients groups as regarding MDA* and GSH* (before phototherapy).....	94
Figure (14):	Receiver Operating Characteristic (ROC) curve analysis of P53, MDA*, GSH*, SOD* and GPx* as regarding cut off point, AUC sensitivity and specificity (before phototherapy).	95
Figure (15):	Comparison between control and patients groups as regarding P53 (before discontinuation of phototherapy).....	97
Figure (16):	Comparison between control and patients groups as regarding MDA* and GSH* (before discontinuation of phototherapy).....	97

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (17):	Receiver Operating Characteristic (ROC) curve analysis of P53, MDA*, GSH*, SOD* and GPx* (before discontinuation of phototherapy) as regarding cut off point, AUC sensitivity and specificity.	98
Figure (18):	Comparison between control and patients groups regarding P53 (72 hrs after discontinuation of phototherapy).....	100
Figure (19):	Comparison between control and patients groups regarding MDA* and GSH* (72 hrs after discontinuation of phototherapy).....	100
Figure (20):	Receiver Operating Characteristic (ROC) curve analysis of P53, MDA*, GSH*, SOD* and GPx* (72 hrs after discontinuation of phototherapy) as regarding cut off point, AUC* sensitivity and specificity.	101
Figure (21):	Comparison among patients group regarding bilirubin, MDA* and GSH*.....	105
Figure (22):	Comparison among patients group regarding P53.....	105
Figure (23):	Correlation between bilirubin and MDA* before discontinuation phototherapy.....	109
Figure (24):	Correlation between bilirubin before and GPx* before discontinuation phototherapy.	109
Figure (25):	Correlation between bilirubin and MDA* 72 hrs after discontinuation of phototherapy.	111
Figure (26):	Correlation between MDA* and SOD* 72 hrs after discontinuation of phototherapy.....	111
Figure (27):	Comparison between males and females as regarding GSH* (before phototherapy).....	113

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (28):	Comparison between males and females as regarding P53 (72 hrs after discontinuation of phototherapy).....	113
Figure (29):	Comparison between mode of delivery (NVD*, CS*) as regarding MDA* and GSH* (before phototherapy)	116
Figure (30):	Comparison between mode of delivery (NVD*, CS*) as regarding MDA* and GSH* (before discontinuation of phototherapy).....	116
Figure (31):	Comparison between mode of delivery (NVD*, CS*) as regarding MDA* and GSH* (72 hrs after discontinuation of phototherapy).....	117

List of Abbreviations

Abb.	Full term
<i>AAP</i>	<i>American Academy of Pediatrics</i>
<i>CMF</i>	<i>Congenital malformations</i>
<i>CRP</i>	<i>C-reactive protein</i>
<i>ELISA</i>	<i>enzyme linked immunosorbent assay</i>
<i>ER</i>	<i>Endoplasmic reticulum</i>
<i>FADD</i>	<i>Fas associated death domain protein</i>
<i>GRx</i>	<i>Glutathione reductase</i>
<i>GSH</i>	<i>Glutathione peroxidase</i>
<i>GST</i>	<i>Glutathione -S- transferase</i>
<i>HIE</i>	<i>Hypoxic ischemic encephalopathy</i>
<i>HO</i>	<i>Heme oxygenase</i>
<i>IR</i>	<i>Infra red</i>
<i>kDa</i>	<i>Kilo Dalton</i>
<i>LED</i>	<i>Light-emitting diode</i>
<i>MDA</i>	<i>Malondialdehyde</i>
<i>NICUs</i>	<i>Neonatal Intensive care unit</i>
<i>OD</i>	<i>Oligomerization domain</i>
<i>ROC</i>	<i>Receiver operating characteristic curve</i>
<i>SOD</i>	<i>Superoxide dismutase</i>
<i>TAD</i>	<i>Transcription –activation domain</i>
<i>UDPGT</i>	<i>Uridine-diphospho-Glucuronic acid transferase</i>
<i>UGT</i>	<i>Uridine diphosphate glucuronyl transferase</i>
<i>UGTs</i>	<i>Uridine diphospho glucuronosyltransferase</i>
<i>UTI</i>	<i>Urinary tract infection</i>
<i>UV</i>	<i>Ultra violet</i>

Abstract

Background: Jaundice is the most common condition that requires medical attention in newborns. Although phototherapy is the standard treatment for neonatal hyperbilirubinemia, it may lead to potential side effects such as retinal degeneration, diarrhea, dehydration, and skin rash. Experimental studies have demonstrated that phototherapy increased apoptosis in the mouse lymphoma cell line and neonatal small intestine cells. It is essential to study the side effects of phototherapy to restrict its use in those with significant hyperbilirubinemia.

Aim: To assess the influence of phototherapy on apoptosis in peripheral blood lymphocytes in full-term infants using an apoptotic marker.

Methods: A case control study was conducted on 50 full term neonates (30 with unconjugated hyperbilirubinemia requiring phototherapy according to American Academy of Pediatrics <AAP> Guidelines and 20 healthy non jaundiced neonates as a control) enrolled from neonatal intensive care unit (NICU). Laboratory investigations including P53 as an apoptotic marker and oxidative stress markers (Malondialdehyde MDA, Reduced glutathione GSH, Superoxide dismutase SOD and Glutathione Peroxidase GPx) were done for the two groups.

Results: There is a significant increase of apoptosis as indicated by a significant increase in P53 induced by phototherapy and hyperbilirubinemia. Our study results also show that Phototherapy has a great effect on oxidative stress markers by increasing Malondialdehyde MDA level, Superoxide Dismutase SOD activity and Glutathione Peroxidase GPx activity and decreasing reduced glutathione GSH level. **Conclusion:** phototherapy induces apoptosis in peripheral blood lymphocytes of full-term infants and has a great effect on oxidative stress markers so Phototherapy use should be restricted to those with significant hyperbilirubinemia.

INTRODUCTION

Jaundice is the most common condition that requires medical attention in newborns. The yellowish discoloration of the skin and sclera in newborns with jaundice is the result of accumulation of unconjugated bilirubin. In most infants, unconjugated hyperbilirubinemia reflects a normal transitional phenomenon (*Manning et al., 2007*).

However, in some infants, serum bilirubin levels may rise excessively, which can be cause for concern because unconjugated bilirubin is neurotoxic and can cause death in newborns and lifelong neurologic sequelae (kernicterus) in infants who survive (*Macias et al., 2009*).

Although phototherapy is the standard treatment for neonatal hyperbilirubinemia, it may lead to potential side effects such as retinal degeneration, diarrhea, dehydration, and skin rash (*Xiong et al., 2011*).

Moreover, experimental studies have demonstrated that phototherapy increased apoptosis in the mouse lymphoma cell line (*Bruzell, 2005*) and neonatal small intestine cells (*Tanaka et al., 2008*).

Peripheral blood lymphocytes are commonly used to monitor environmentally induced genetic damage. P53 is a tumor suppressor protein that regulates the cell cycle and, thus, functions as a tumor suppressor that is involved in preventing

cancer. As such, P53 has been described as “the guardian of the genome” because of its role in conserving stability by preventing genome mutation. One of the most dramatic responses to P53 activation is the induction of apoptosis (*Jiang et al., 2015*).

AIM OF THE WORK

To assess the influence of phototherapy on apoptosis in peripheral blood lymphocytes in full-term infants using an apoptotic marker.